Table 1.
STING agonists in clinical development.
| Drug Candidates | Developers | Molecular Type | Administration Route | First Clinical Study Initiation | Clinical Study1 | Ref.2 |
|---|---|---|---|---|---|---|
| ADU-S100 | Aduro Biotech (acquired by Chinook Therapeutics) | CDN analog | IT | Mar-16 | NCT02675439 | [22] |
| NCT03172936 | [13], [14] | |||||
| NCT03937141 | ||||||
| MK-1454 | Merck Sharp & Dohme Corp | CDN analog | IT | Feb-17 | NCT03010176 | [23] |
| NCT04220866 | ||||||
| MK-2118 | Merck Sharp & Dohme | non-CDN molecule | IT/SC | Sep-17 | NCT03249792 | |
| GSK-3745417 | GlaxoSmithKline | non-CDN molecule | IV | Mar-19 | NCT03843359 | |
| BMS-986301 | Bristol-Myers Squibb, IFM Therapeutics | CDN analog | IV/IT/IM | Mar-19 | NCT03956680 | [24] |
| SB-11285 | F-star Therapeutics, Spring Bank Pharmaceuticals | CDN analog | IV | Sep-19 | NCT04096638 | [25] |
| IMSA-101 | Genor Biopharma; ImmuneSensor Therapeutics | CDN analog | IT | Sep-19 | NCT04020185 | |
| SYN-STING (SYNB1891) | Synlogic | Engineered bacteria vectors | IT | Nov-19 | NCT04167137 | [19], [20] |
| BI-1387446 | Boehringer Ingelheim | CDN analog | IT | Mar-20 | NCT04147234 | |
| TAK-676 | Takeda Oncology | CDN analog | IV | Mar-20 | NCT04420884 | |
| NCT04879849 | ||||||
| E-7766 | Eisai | non-CDN molecule | IT | Mar-20 | NCT04144140 | [26] |
| exoSTING | Codiak BioSciences Inc | extracellular vesicle loaded with CDN | IT | Sep-20 | NCT04592484 | [21] |
| SNX281 | Silicon therapeutics | non-CDN molecule | IV | Nov-20 | NCT04609579 | |
| HG-381 | HitGen Ltd | non-CDN molecule | IV | Aug-21 | NCT04998422 | |
| DN-015089 | Shanghai De Novo Pharmatech | undisclosed | IT | Oct-21 | CTR20212462 |
1
The designs of clinical studies with a NCT code could be identified in https://clinicaltrials.gov/.
2
References of pre-clinical studies and current clinical study data are listed in the table. Abbreviations: CDN, cyclic dinucleotide; IT, intratumoral; IV, intravenous; IM, intramuscular; SC, subcutaneous.